TAT-N24穿膜融合多肽对前列腺癌细胞增殖的影响  

Effects of Cell-Permeable TAT-N24 Fusion Peptide on Prostate Cancer Cell Proliferation

作　　者：邓豫 王桂华[1] 左学良[1] 董硕[1] 金源[1] 李维娜[2] 龚建平[1] 胡俊波[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤研究所/胃肠外科,武汉430030 [2]华中科技大学同济医学院附属同济医院感染性疾病研究所,武汉430030

出　　处：《医药导报》2011年第7期843-845,共3页Herald of Medicine

基　　金：国家重点基础研究发展计划(973计划)项目(基金编号:2009CB521802);国家自然科学基金资助项目(基金编号:30872472,30973496,30800569);湖北省自然科学基金资助项目(基金编号:2008CDB174,2009CDB239)

摘　　要：目的观察TAT-N24穿膜融合多肽抑制前列癌细胞增殖的作用。方法用纯化的TAT-N24穿膜融合多肽处理前列癌PC3细胞,采用流式细胞仪检测细胞周期进程的改变,BrdU掺入法检测其对细胞DNA合成的影响,Western blot法检测细胞内AKT蛋白的磷酸水平的变化。结果①细胞周期分布:空白组G0/G1期(56.9±6.1)%,S期(27.0±2.3)%,G2/M期(16.1±1.3)%;对照多肽组G0/G1期(57.9±4.8)%,S期(24.2±3.1)%,G2/M期(27.8±1.4)%;TAT-N24组G0/G1期(68.6±5.4)%(P<0.05),S期(19.4±1.5)%(P<0.05),G2/M期(12.3±1.4)%。②BrdU阳性细胞为空白组(37.9±3.2)%,对照多肽组(36.2±4.1)%,TAT-N24组(21.5±2.4)%(P<0.05);③AKT磷酸化水平组间差异无统计学意义。结论 TAT-N24穿膜融合多肽能有效阻滞前列腺癌PC3细胞的细胞周期进程,并抑制其DNA合成。TAT-N24穿膜融合多肽有望成为有效的治疗前列腺癌的分子靶向药物。Objective To investigate the anti-proliferation effects of cell-permeable TAT-N24 fusion peptide on prostate cancer cells. Methods The human prostate cancer cell line PC3 was treated with TAT-N24,cell cycle distribution was analyzed by flow cytometry,DNA synthesis of which was measured by BrdU incorporation assay.and the expression of phosphorylated AKT was examined by Western blot analysis. Results ① G0/G1 phase arrest induced by TAT-N24 was observed.The cell cycle distribution was that： in the blank group G0/G1 phase as（56.9±6.1）%,S phase（27.0±2.3）%,G2/M phase（16.1±1.3）%;G0/G1 phase（57.9±4.8）%,S phase（24.2±3.1）%,G2/M phase（27.8±1.4）% in the control peptide group;G0/G1 phase（68.6±5.4）%（P0.05）,S phase（19.4±1.5）%（P0.05）,G2/M phase（12.3±1.4）% in TAT-N24 group,respectively.②The BrdU positive cells in the blank,control peptide and TAT-N24 groups was（37.9±3.2）%,（36.2±4.1）%,（21.5±2.4）%（P0.05）,respectively;③It was revealed that TAT-N24 had no significant effects on AKT phosphorylation Conclusion The cell-permeable TAT-N24 fusion peptide effectively blocks cells processing into G0/G1 phase and inhibiting DNA synthesis of PC3 cell line.TAT-N24 may become an effective molecular targeted gene medicine for cancer therapy.

关 键 词：TAT-N24穿膜融合多肽 前列腺癌细胞 分子靶向治疗 

分 类 号：R977.6[医药卫生—药品]